MedPath

IHEEZO

These highlights do not include all the information needed to use IHEEZO safely and effectively. See full prescribing information for IHEEZO . IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3%, for topical ophthalmic use Initial U.S. Approval: 1955

Approved
Approval ID

ea3b2d2c-8b33-d199-e053-2995a90a699c

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 21, 2023

Manufacturers
FDA

Harrow Eye, LLC

DUNS: 118526951

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

chloroprocaine hydrochloride ophthalmic gel

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code82667-300
Application NumberNDA216227
Product Classification
M
Marketing Category
C73594
G
Generic Name
chloroprocaine hydrochloride ophthalmic gel
Product Specifications
Route of AdministrationOPHTHALMIC
Effective DateFebruary 21, 2023
FDA Product Classification

INGREDIENTS (4)

CHLOROPROCAINE HYDROCHLORIDEActive
Quantity: 24 mg in 800 mg
Code: LT7Z1YW11H
Classification: ACTIB
WATERInactive
Code: 059QF0KO0R
Classification: IACT
HYDROXYETHYL CELLULOSE, UNSPECIFIEDInactive
Code: T4V6TWG28D
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

IHEEZO - FDA Drug Approval Details